Chembio has developed a testing approach known as Dual Path Platform technology, which can help in the rapid diagnosis of HIV, influenza A and B, and hepatitis B and C.
The point-of-care assays require a blood sample or oral fluid sample and can diagnose the disease in 15 minutes.
The assays are designed to significantly shorten the time to diagnosis and lessen the cost of testing.
Chembio Diagnostics CEO Lawrence Siebert said Dual Path Platform assays can incorporate a cassette with up to five test lines on it, each of which is capable of confirming the presence of a specific condition at the same time.
“If performed immediately before an organ donation, this test would deliver results within minutes and considerably lessen the chances of an infected organ being transplanted into a patient,” Siebert said.
Related Companies
